NONFLUENT VARIANT PRIMARY PROGRESSIVE APHASIA (NFVPPA)
Clinical trials for NONFLUENT VARIANT PRIMARY PROGRESSIVE APHASIA (NFVPPA) explained in plain language.
Never miss a new study
Get alerted when new NONFLUENT VARIANT PRIMARY PROGRESSIVE APHASIA (NFVPPA) trials appear
Sign up with your email to follow new studies for NONFLUENT VARIANT PRIMARY PROGRESSIVE APHASIA (NFVPPA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug aims to slow language loss in rare brain disease
Disease control Recruiting nowThis early-stage study tests an experimental drug called neflamapimod in 20 people with a rare form of dementia that mainly affects speech and language, known as nonfluent variant primary progressive aphasia (nfvPPA). The goal is to see if the drug is safe and whether it can help…
Matched conditions: NONFLUENT VARIANT PRIMARY PROGRESSIVE APHASIA (NFVPPA)
Phase: PHASE2 • Sponsor: EIP Pharma Inc • Aim: Disease control
Last updated Jun 24, 2026 02:34 UTC
-
New virtual therapy aims to help dementia patients communicate better with loved ones
Symptom relief Recruiting nowThis study tests a personalized, virtual speech therapy program for people with primary progressive aphasia (a type of dementia that affects language) and their communication partners. The goal is to see if the program improves communication and quality of life. About 30 particip…
Matched conditions: NONFLUENT VARIANT PRIMARY PROGRESSIVE APHASIA (NFVPPA)
Phase: NA • Sponsor: Maya Henry • Aim: Symptom relief
Last updated Jun 10, 2026 13:26 UTC